Biologic therapy for rheumatoid arthritis in developing countries-a place for non-TNF inhibitors as first-line treatment?: Reducing the risk of TB co-morbidity

Rheumatology (United Kingdom)

Volumn 54, Issue 2, 2015, Pages 208-209

  Tikly, Mohammed ^a   Hodkinson, Bridget ^a,b   Dheda, Keertan ^b  

^a UNIVERSITY OF THE WITWATERSRAND   (South Africa)

^b UNIVERSITY OF CAPE TOWN   (South Africa)

Author keywords

[No Author keywords available]

Indexed keywords

ABATACEPT; ISONIAZID; RITUXIMAB; TOCILIZUMAB; TUMOR NECROSIS FACTOR INHIBITOR; ANTIRHEUMATIC AGENT; BIOLOGICAL FACTOR; BIOLOGICAL PRODUCT; TUMOR NECROSIS FACTOR;

BCG VACCINATION; BIOLOGICAL THERAPY; CHEMOPROPHYLAXIS; DEVELOPING COUNTRY; DISEASE ERADICATION; EARLY DIAGNOSIS; EDITORIAL; ENDEMIC DISEASE; GUINEA PIG; HEALTH CARE PERSONNEL; HEPATITIS B; HUMAN; INTERFERON GAMMA RELEASE ASSAY; LATENT TUBERCULOSIS; LIVER TOXICITY; MEMORY T LYMPHOCYTE; MYCOBACTERIUM TUBERCULOSIS; NONHUMAN; OBSERVATIONAL STUDY; POLYMERASE CHAIN REACTION; PREDICTIVE VALUE; PRESCRIPTION; PRIORITY JOURNAL; PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RHEUMATOID ARTHRITIS; SCREENING TEST; SENSITIVITY AND SPECIFICITY; SOCIAL STATUS; TUBERCULIN TEST; UNITED STATES; ANTAGONISTS AND INHIBITORS; ARTHRITIS, RHEUMATOID; COMPLICATION; DRUG RESISTANCE; PROCEDURES; RISK FACTOR; TUBERCULOSIS;

ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; BIOLOGICAL FACTORS; BIOLOGICAL PRODUCTS; BIOLOGICAL THERAPY; DEVELOPING COUNTRIES; DRUG RESISTANCE; EARLY DIAGNOSIS; HUMANS; RISK FACTORS; TUBERCULOSIS; TUMOR NECROSIS FACTORS;

EID: 84925581826     PISSN: 14620324     EISSN: 14620332     Source Type: Journal    
DOI: 10.1093/rheumatology/keu040     Document Type: Editorial

References (10)

1. Tubach F, Salmon D, Ravaud P et al. Risk of tuberculosis is higher with anti-tumor necrosis factor monoclonal antibody therapy than with soluble tumor necrosis factor receptor therapy: the three-year prospective French Research Axed on Tolerance of Biotherapies registry. Arthritis Rheum 2009;60:1884-94.
2. Lee SK, Kim SY, Jung JY et al. Mycobacterial infections in patients treated with tumor necrosis factor antagonists in South Korea. Lung 2013;191:565-71.
3. Dheda K, van Zyl Smit R, Badri M, Pai M. T-cell interferongamma release assays for the rapid immunodiagnosis of tuberculosis: clinical utility in high-burden vs. lowburden settings. Curr Opin Pulm Med 2009;15:188-200.
4. Zumla A, Atun R, Maeurer M et al. Viewpoint: scientific dogmas, paradoxes and mysteries of latent Mycobacterium tuberculosis infection. Trop Med Int Health 2011;16:79-83.
5. Barrios-Payan J, Saqui-Salces M, Jeyanathan M et al. Extrapulmonary locations of Mycobacterium tuberculosis DNA during latent infection. J Infect Dis 2012;206:1194-05.
6. Rangaka MX, Wilkinson KA, Glynn JR et al. Predictive value of interferon-gamma release assays for incident active tuberculosis: a systematic review and metaanalysis. Lancet Infect Dis 2012;12:45-55.
7. Sichletidis L, Settas L, Spyratos D, Chloros D, Patakas D. Tuberculosis in patients receiving anti-TNF agents despite chemoprophylaxis. Int J Tuberc Lung Dis 2006;10:1127-32.
8. Ferebee SH. Controlled chemoprophylaxis trials in tuberculosis. A general review. Bibl Tuberc 1970;26:28-106.
9. Hodkinson B, Van Duuren E, Pettipher C, Kalla A. South African recommendations for the management of rheumatoid arthritis: an algorithm for the standard of care in 2013. S Afr Med J 2013;103:576-85.
10. Ruderman EM. Overview of the safety of non-biologic and biologic DMARDs. Rheumatology 2012;51(Suppl 6): vi37-43.